REPLIMUNE GROUP, INC. Comprehensive Income
REPLIMUNE GROUP, INC. (REPL) reported Comprehensive Income of -$69.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$69.19M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$73.38M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$70.49M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$82.22M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2026 was -$313.99M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$246.70M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$216.67M.
- REPLIMUNE GROUP, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$167.58M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$69.19M 10-Q · filed 2026-08-14 | -$142.57M derived: sum of 2 quarters · filed 2026-08-14 | -$213.06M derived: sum of 3 quarters · filed 2026-08-14 | -$295.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$73.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$143.87M derived: sum of 2 quarters · filed 2026-06-29 | -$226.09M derived: sum of 3 quarters · filed 2026-06-29 | -$313.99M 10-K · filed 2026-06-29 |
| 2025-12-31 | -$70.49M 10-Q · filed 2026-02-03 | -$152.71M derived: sum of 2 quarters · filed 2026-02-03 | -$240.61M 10-Q · filed 2026-02-03 | -$315.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$82.22M 10-Q · filed 2025-11-06 | -$170.12M 10-Q · filed 2025-11-06 | -$244.96M derived: sum of 3 quarters · filed 2026-08-14 | -$308.77M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$87.90M 10-Q · filed 2026-08-14 | -$162.74M derived: sum of 2 quarters · filed 2026-08-14 | -$226.56M derived: sum of 3 quarters · filed 2026-08-14 | -$280.30M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$74.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | -$138.66M derived: sum of 2 quarters · filed 2026-06-29 | -$192.40M derived: sum of 3 quarters · filed 2026-06-29 | -$246.70M 10-K · filed 2026-06-29 |
| 2024-12-31 | -$63.81M 10-Q · filed 2026-02-03 | -$117.56M derived: sum of 2 quarters · filed 2026-02-03 | -$171.86M 10-Q · filed 2026-02-03 | -$226.82M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | -$53.74M 10-Q · filed 2025-11-06 | -$108.05M 10-Q · filed 2025-11-06 | -$163.00M derived: sum of 3 quarters · filed 2025-11-06 | -$214.88M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$54.30M 10-Q · filed 2025-08-07 | -$109.26M derived: sum of 2 quarters · filed 2025-08-07 | -$161.13M derived: sum of 3 quarters · filed 2025-08-07 | -$219.65M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$54.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | -$106.83M derived: sum of 2 quarters · filed 2025-05-22 | -$165.35M derived: sum of 3 quarters · filed 2025-05-22 | -$216.67M 10-K · filed 2025-05-22 |
| 2023-12-31 | -$51.87M 10-Q · filed 2025-02-12 | -$110.40M derived: sum of 2 quarters · filed 2025-02-12 | -$161.71M 10-Q · filed 2025-02-12 | -$208.96M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$58.52M 10-Q · filed 2024-11-12 | -$109.84M 10-Q · filed 2024-11-12 | -$157.09M derived: sum of 3 quarters · filed 2024-11-12 | -$195.97M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$51.32M 10-Q · filed 2024-08-08 | -$98.57M derived: sum of 2 quarters · filed 2024-08-08 | -$137.45M derived: sum of 3 quarters · filed 2024-08-08 | -$178.14M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$47.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | -$86.13M derived: sum of 2 quarters · filed 2024-05-16 | -$126.82M derived: sum of 3 quarters · filed 2024-05-16 | -$167.58M 10-K · filed 2024-05-16 |
| 2022-12-31 | -$38.88M 10-Q · filed 2024-02-08 | -$79.57M derived: sum of 2 quarters · filed 2024-02-08 | -$120.33M 10-Q · filed 2024-02-08 | -$152.82M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | -$40.69M 10-Q · filed 2023-11-07 | -$81.45M 10-Q · filed 2023-11-07 | -$113.94M derived: sum of 3 quarters · filed 2023-11-07 | -$143.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$40.76M 10-Q · filed 2023-08-03 | -$73.25M derived: sum of 2 quarters · filed 2023-08-03 | -$103.11M derived: sum of 3 quarters · filed 2023-08-03 | -$132.25M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$32.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | -$62.35M derived: sum of 2 quarters · filed 2023-05-18 | -$91.49M derived: sum of 3 quarters · filed 2023-05-18 | -$118.61M 10-K · filed 2023-05-18 |
| 2021-12-31 | -$29.86M 10-Q · filed 2023-02-09 | -$59.00M derived: sum of 2 quarters · filed 2023-02-09 | -$86.13M 10-Q · filed 2023-02-09 | -$107.90M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | -$29.14M 10-Q · filed 2022-11-03 | -$56.26M 10-Q · filed 2022-11-03 | -$78.04M derived: sum of 3 quarters · filed 2022-11-03 | -$99.33M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$27.13M 10-Q · filed 2022-08-04 | -$48.90M derived: sum of 2 quarters · filed 2022-08-04 | -$70.19M derived: sum of 3 quarters · filed 2022-08-04 | -$89.71M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$21.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | -$43.06M derived: sum of 2 quarters · filed 2022-05-19 | -$62.58M derived: sum of 3 quarters · filed 2022-05-19 | -$80.28M 10-K · filed 2022-05-19 |
| 2020-12-31 | -$21.29M 10-Q · filed 2022-02-03 | -$40.80M derived: sum of 2 quarters · filed 2022-02-03 | -$58.51M 10-Q · filed 2022-02-03 | -$74.23M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | -$19.52M 10-Q · filed 2021-11-04 | -$37.22M 10-Q · filed 2021-11-04 | -$52.94M derived: sum of 3 quarters · filed 2021-11-04 | -$68.75M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$17.70M 10-Q · filed 2021-08-06 | -$33.42M derived: sum of 2 quarters · filed 2021-08-06 | -$49.23M derived: sum of 3 quarters · filed 2021-08-06 | -$60.63M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | -$15.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | -$31.53M derived: sum of 2 quarters · filed 2021-05-20 | -$42.93M derived: sum of 3 quarters · filed 2021-05-20 | -$52.55M 10-K · filed 2021-05-20 |
| 2019-12-31 | -$15.81M 10-Q · filed 2021-02-04 | -$27.20M derived: sum of 2 quarters · filed 2021-02-04 | -$36.83M 10-Q · filed 2021-02-04 | -$43.16M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | -$11.40M 10-Q · filed 2020-11-05 | -$21.02M 10-Q · filed 2020-11-05 | -$27.35M derived: sum of 3 quarters · filed 2020-11-05 | -$35.18M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$9.63M 10-Q · filed 2020-08-07 | -$15.96M derived: sum of 2 quarters · filed 2020-08-07 | -$23.79M derived: sum of 3 quarters · filed 2020-08-07 | -$30.42M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$14.16M derived: sum of 2 quarters · filed 2020-06-03 | -$20.80M derived: sum of 3 quarters · filed 2020-06-03 | -$31.65M 10-K · filed 2020-06-03 |
| 2018-12-31 | -$7.83M 10-Q · filed 2020-02-13 | -$14.46M derived: sum of 2 quarters · filed 2020-02-13 | -$25.32M 10-Q · filed 2020-02-13 | -$31.54M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | -$6.63M 10-Q · filed 2019-11-12 | -$17.49M 10-Q · filed 2019-11-12 | -$23.71M derived: sum of 3 quarters · filed 2020-06-03 | -$27.96M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | -$10.86M 10-Q · filed 2019-08-14 | -$17.08M derived: sum of 2 quarters · filed 2020-06-03 | -$21.32M derived: sum of 3 quarters · filed 2020-06-03 | -$25.36M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | -$6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | -$10.47M derived: sum of 2 quarters · filed 2020-06-03 | -$14.50M derived: sum of 3 quarters · filed 2020-06-03 | -$17.39M 10-K · filed 2020-06-03 |
| 2017-12-31 | -$4.25M 10-Q · filed 2019-02-14 | -$8.28M derived: sum of 2 quarters · filed 2019-02-14 | -$11.17M 10-Q · filed 2019-02-14 | |
| 2017-09-30 | -$4.04M 10-Q · filed 2018-11-14 | -$6.63M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$2.60M 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | -$9.14M 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |